Results 51 to 60 of about 16,753 (223)
Varenicline for cannabis use disorder: A randomized controlled trial
Addiction, EarlyView.Abstract Background and aims
Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner +8 morewiley +1 more sourceAddiction‐related problems in Japan: A regional perspective
Addiction, EarlyView.Abstract
Japan's addiction landscape appears paradoxical. The lifetime use of illicit drugs is among the lowest in Organisation for Economic Cooperation and Development countries, but harm from alcohol, tobacco, and gambling ranks among the world's highest.Soichiro Ide, Yoko Nishitani, Masahiko Sumitani, Masabumi Minami, Tadashi Isa, Masako Iseki, Michiko Ohkura, Hitoshi Okamoto, Tetsuro Kikuchi, Yuko Sekino, Hidehiko Takahashi, Kenji Takeuchi, Atsumi Nitta, Takeshi Honjo, Hiroshi Matsumoto, Tsuyoshi Miyakawa, Toshiya Murai, Toshihiko Matsumoto, Kazuyuki Nakagome, Kazutaka Ikeda +19 morewiley +1 more sourceNew Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What has been Investigated and What is in the Pipeline? [PDF]
, 2016 A wide range of support is available to help smokers to quit and aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion.A Bisaga, A Jackson, A Kukkar, A Lenox-Smith, A Mann, A Parsons, A Sood, A Sood, A Verrotti, AE Evins, AH Glassman, AK Shinn, AM Joseph, AR Buchhalter, AS Rauhut, AV Prochazka, B Gaster, B Pasternak, B Spring, B Westenberger, BA Johnson, BF Grant, BM Kuehn, C Bullen, C Lerman, C Reavill, C Zona, C-Y Yeh, CA Martin, CD Cropp, CE Gartner, CF Koegelenberg, CL Bennett, CL DeVane, CL Strasinger, CT Bolliger, D Gonzales, D Hammond, D Kotz, D Kotz, D Kotz, D Mischoulon, D Moore, DA Baker, DA Baltieri, DA Revicki, Damian M. Cummings, DE Hilleman, DJ Romberger, DK Hatsukami, DK Hatsukami, DK Miller, DP Tashkin, E Beard, E Beard, E Beard, E Gere-Pászti, E Nowakowska, EA Finkelstein, EA Gilpin, EA McClure, EA Zimovetz, EC Westman, ED Levin, EG Guy, EH Cerny, EJ Jensen, EJ Mills, EJ Mills, EJ Wagena, Emma Beard, EW Tuan, F Wang, FT Filippidis, G Addolorato, G Chiara Di, G Cucchiaro, G Sutherland, GA Higgins, GM Keating, H Kitagawa, H McRobbie, H McRobbie, H Minami, H Myrick, H Pine-Abata, H-J Aubin, HM Schuller, I Berlin, J Balmford, J Brown, J Cornuz, J Foulds, J Foulds, J Kaper, J Kay, J Leaviss, J Ollivier, J Rose, J Shearer, J Shearer, J Yang, J-F Etter, J-G Gehricke, JA Dani, JE Henningfield, JE Henningfield, JE Rose, JE Rose, JE Sarginson, JF Rosenbaum, JM Ramon, JM Samet, JN Liberman, JO Ebbert, JO Ebbert, JR DiFranza, JR Hughes, JR Hughes, JS Ballon, JS Brown, JS Fowler, JW Lockner, K Bolin, K Demyttenaere, K Hara, K Ogita, K Silla, KA Holes-Lewis, KA Kasza, KA Perkins, KA Sacco, KC Waterman, KE Dunn, KE Farsalinos, KH Thomas, KP Garnock-Jones, KS Paudel, L Annemans, L Kozlowski, L Leggio, L Lima De, L Schmaal, L Shahab, L Shahab, LF Gaal Van, LH Ferry, Lion Shahab, LS Brose, LS Brose, LS Covey, M Farrell, M Harrison-Woolrych, M Hoogendoorn, M Khalifa, M Lader, M Mahmoudi, M McCarty, M Mugnaini, M Mula, M Neovius, M Ng, M Pravetoni, M Pravetoni, M Raw, M Raw, M Sofuoglu, M Sofuoglu, M Sofuoglu, M Sofuoglu, M Williams, M Wimbiscus, MA Jacobs, MA Russell, MA Russell, MC Fiore, ME Hadwiger, ME Jarvik, ME Jarvik, ME Mooney, ME Page, ME Thase, MFG Murphy, MG LeSage, MG LeSage, MH Ebell, MH Rapaport, ML Goniewicz, MM Moran, MY Bertram, N Benowitz, N Lindblom, N Walker, N Woolacott, NB Edwards, NF Woolacott, NL Benowitz, P Aveyard, P Farid, P Franks, P Gerrard, P Hajek, P Hajek, P Hajek, P Hajek, P Jha, P Maurer, P Popik, PH Hoogsteder, PH Silverstone, PM Bet, PM Cinciripini, PS Masand, R Benyamin, R Freedman, R Niaura, R Niaura, R Ray, R Richmond, R Shytle, R Taylor, R West, R West, R West, R West, R West, R West, R West, RA Brown, RA Schnoll, RA Schnoll, RB Barlow, RC Smith, RD Hurt, RD Hurt, RE Fahim, RF Yoshimura, RM Anthenelli, RM Pinder, Robert West, S Brimijoin, S Denford, S Greenland, S Leonard, S Shiffman, S Shiffman, S Shiffman, S Shiffman, S Singh, S Thornley, S Tonstad, S Tonstad, S Wanwimolruk, SA Ornish, SC Licata, SD Hall, SD Satoskar, SE Adkison, SH Villiers de, SL McElroy, SM Boekholdt, SM Holliday, SP Lakshmi, SS Hecht, Susan Michie, T Blondal, T Green, T Paparrigopoulos, T Raupach, TB Johnstone, TE Langley, TE Meyer, TJ Meine, TL Awtry, TM Luger, TR Franklin, U Eckstein-Ludwig, U Perngparn, V Butterweck, V Gligorijevic, V Klimek, V Varga, V Vengeliene, VS Kumar, W Berrettini, W Hao, W Pichayakorn, W Qiumei, WI Najm, WR Hiatt, X Shen, Y Buggy, Y Khazaal, Y-S Kim +293 morecore +1 more sourceAdvances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review
Asia-Pacific Journal of Clinical Oncology, EarlyView.Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau +7 morewiley +1 more sourceIdentifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review
BMC Public HealthBackground Adhering to varenicline has been shown to significantly improve the chances of successfully quitting smoking, with studies indicating a twofold increase in 6-month quit rates.Nadia Minian, Melissa Wong, Sowsan Hafuth, Terri Rodak, Alma Rahimi, Dea Gjomema, Jonathan Rose, Laurie Zawertailo, Matt Ratto, Peter Selby +9 moredoaj +1 more sourceNicotine receptor partial agonists for smoking cessation
São Paulo Medical JournalBACKGROUND: Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist)Kate Cahill, Lindsay F. Stead, Tim Lancaster, Igor Bastos Polonio +3 moredoaj +1 more sourceUse of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study
BMC Medicine, 2020 Background Varenicline, bupropion and nicotine replacement therapy (NRT) are three effective pharmacotherapies for smoking cessation, but data about their safety in pregnancy are limited.Duong Thuy Tran, David B. Preen, Kristjana Einarsdottir, Anna Kemp-Casey, Deborah Randall, Louisa R. Jorm, Stephanie K. Y. Choi, Alys Havard +7 moredoaj +1 more source
